Biotech | May 16, 2022
Inmagene receives USFDA IND clearance for a third-generation BTK inhibitor
It is developing the drug candidate to potentially treat immunological diseases
It is developing the drug candidate to potentially treat immunological diseases
Pharmapack offers the platform that enables Bharat Rubber Works to convey its story while simultaneously demonstrating the extraordinary advancements by the company in the field of pharmaceutical packaging
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
East Syracuse site to serve as the LOTTE Center for North America Operations for LOTTE’s biologics contract development and manufacturing organization (CDMO) business
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
It is a new class of drug that treats uncontrolled LDLCholesterol, despite the use of a maximum tolerated dose of statins
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
Subscribe To Our Newsletter & Stay Updated
